Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 1, 2010, Pages 55-63

  Eshhar, Zelig ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Adoptive cancer immunotherapy; Cancer vaccination; Chimeric receptor; Gene modified T cell; T cell receptor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FOLATE BINDING PROTEIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; T LYMPHOCYTE RECEPTOR;

B CELL LYMPHOMA; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DNA MODIFICATION; GASTROINTESTINAL CARCINOMA; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; KIDNEY CARCINOMA; NEOPLASM; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OVARY TUMOR; PASSIVE IMMUNIZATION; PROSTATE ADENOCARCINOMA; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TRANSGENE;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 76749142414     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med (2004) 10(9): 909-915.
2. Genetic Engineering & Biotechnology News: Dendreon reports PROVENGE regulatory and commercialization progress and future pipeline plans at analyst event. Press Release (2009): September 24.
3. Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev Immunol (2009) 27:83-117.
4. Amadori S, Stasi R: Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia. Curr Opin Hematol (2008) 15(2):95-100.
5. Christian BA, Lin TS: Antibody therapy for chronic lymphocytic leukemia. Semin Hematol (2008) 45(2):95-103.
6. Gross G, Waks T, Eshhar Z: Expression of immunoglobulin- T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA (1989) 86(24):10024-10029.
7. Eshhar Z, Waks T, Gross G, Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA (1993) 90(2):720-724.
8. Finney HM, Lawson AD, Bebbington CR, Weir AN: Chimeric receptors providing both primary and co-stimulatory signaling in T cells from a single gene product. J Immunol (1998) 161(6):2791-2797.
9. Finney HM, Akbar AN, Lawson AD: Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR ζ chain. J Immunol (2004) 172(1):104-113.
10. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG et al: Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA (2009) 106(9):3360-3365.
11. Eshhar Z: The T-body approach: Redirecting T cells with antibody specificity. In: Therapeutic Antibodies. Nissim A, Chernajovsky Y (Eds), Springer-Verlag Berlin Heidelberg, Berlin, Germany (2008) 181:329-342.
12. Marcu-Malina V, van Dorp S, Kuball J: Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. Expert Opin Biol Ther (2009) 9(5):579-591.
13. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 21(2):233-240.
14. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 8(4):299-308.
15. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 26(32):5233-5239.
16. de Witte MA, Coccoris M, Wolkers MC, van den Boom MD, Mesman EM, Song JY, van der Valk M, Haanen JB, Schumacher TN: Targeting self-antigens through allogeneic TCR gene transfer. Blood (2006) 108(3):870-877.
17. Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH et al: DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood (2008) 112(7):2956-2964.
18. Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, Li Y, Molloy PE, Dunn SM, Jakobsen BK, Rosenberg SA et al: High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol (2007) 179(9):5845-5854.
19. Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, Strong R, Theobald M, Greenberg PD: Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med (2009) 206(2):463-475.
20. Bendle GM, Haanen JB, Schumacher TN: Preclinical development of T cell receptor gene therapy. Curr Opin Immunol (2009) 21(2):209-214.
21. Bridgeman JS, Gilham DE, Hawkins RE, Cheadle EJ: Meeting Report: The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, Italy. Cancer Immunol Immunother (2009):doi:10.1007/s00262-009-0748-x.
22. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA: Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res (2006) 66(17): 8878-8886.
23. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA: Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res (2007) 67(8):3898-3903.
24. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, Greenberg PD: Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood (2007) 109(6):2331-2338.
25. Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RL: Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther (2000) 7(16):1369-1377.
26. Sebestyén Z, Schooten E, Sals T, Zaldivar I, San José E, Alarcón B, Bobisse S, Rosato A, Szöllosi J, Gratama JW, Willemsen RA et al: Human TCR that incorporate CD3ζ induce highly preferred pairing between TCRα and β chains following gene transfer. J Immunol (2008) 180(11):7736-7746.
27. Willemsen R, Chames P, Schooten E, Gratama JW, Debets R: Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy. Cytometry A (2008) 73(11):1093-1099.
28. Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, Reiter Y: Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res (2008) 68(15):6360-6367.
29. Frank NY, Schatton T, Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 120(1): 41-50.
30. Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC et al: Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: Selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res (2009) 69(20):8058-8066.
31. Kmieciak M, Knutson KL, Dumur CI, Manjili MH: HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol (2007) 37(3):675-685.
32. Zhang B, Karrison T, Rowley DA, Schreiber H: IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest (2008) 118(4):1398-1404.
33. Schmitt TM, Ragnarsson GB, Greenberg PD: T cell receptor gene therapy for cancer. Hum Gene Ther (2009) 20(11):1240-1248.
34. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, Dunn S, Liddy N, Jacob J, Jakobsen BK, Boulter JM: Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol (2005) 23(3):349-354.
35. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H: T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol (2004) 173(12):7647-7653.
36. Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E, Kleber S, Nuber N, Stenner-Liewen F, Bauer S, McMichael A et al: Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci USA (2009) 106(14):5784-5788.
37. Richman SA, Aggen DH, Dossett ML, Donermeyer DL, Allen PM, Greenberg PD, Kranz DM: Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain VαVβ fragments. Mol Immunol (2009) 46(5):902-916.
38. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 183(9):5563-5574.
39. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL: T cell retargeting with MHC class I-restricted antibodies: The CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol (2005) 174(12):7853-7858.
40. Patel SG, Ge Y, Moskalenko M, McArthur JG: Anti-Tumor CC49-ζ CD4 T cells possess both cytolytic and helper functions. J Immunother (2000) 23(6):661-668.
41. Junghans R, Safar M, Huberman M, Ma Q, Ripley R, Leung S, Beecham EJ: Preclinical and phase I data of anti-CEA designer T cell therapy for cancer: A new immunotherapeutic modality. Proc Am Soc Clin Oncol (2001) 37:A1063.
42. Emtage PC, Lo AS, Gomes EM, Liu DL, Gonzalo-Daganzo RM, Junghans RP: Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: A preclinical evaluation. Clin Cancer Res (2008) 14(24):8112-8122.
43. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC et al: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 12(20 Pt 1):6106-6115.
44. Lamers CH, Sleijfer S, Willemsen RA, Debets R, Kruit WH, Gratama JW, Stoter G: Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes. J Biol Regul Homeost Agents (2004) 18(2):134-140.
45. Lamers CH, Sleijfer S, Willemsen RA, Debets R, Kruit WH, Gratama JW, Stoter G: Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes. J Biol Regul Homeost Agents (2004) 18(2):134-140.
46. Lamers CH, Langeveld SC, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW: Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgenespecific immune functions in vivo. Cancer Immunol Immunother (2007) 56(12):1875-1883.
47. Tran CA, Burton L, Russom D, Wagner JR, Jensen MC, Forman SJ, DiGiusto DL: Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: An approach to improving product safety, composition, and production capacity. J Immunother (2007) 30(6):644-654.
48. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther (2007) 15(4):825-833.
49. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK et al: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 112(6): 2261-2271.
50. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E et al: Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 14(11):1264-1270.
51. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar B, Zhou X: 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 21(1):75-86.
52. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Rivière I, Sadelain M: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 9(3):279-286.
53. Numbenjapon T, Serrano LM, Chang WC, Forman SJ, Jensen MC, Cooper LJ: Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. Exp Hematol (2007) 35(7):1083-1090.
54. Huarte E, Fisher J, Turk MJ, Mellinger D, Foster C, Wolf B, Meehan KR, Fadul CE, Ernstoff MS: Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 285(1):80-88.
55. Overwijk WW, Schluns KS: Functions of γC cytokines in immune homeostasis: Current and potential clinical applications. Clin Immunol (2009) 132(2):153-165.
56. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC et al: Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA (2009) 106(41):17469-17474.
57. Bendle GM, Haanen JB, Schumacher TN: Preclinical development of T cell receptor gene therapy. Curr Opin Immunol (2009) 21(2):209-214.
58. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314(5796):126-129.
59. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD et al: Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 180(9): 6116-6131.
60. Dossett ML, Teague RM, Schmitt TM, Tan X, Cooper LJ, Pinzon C, Greenberg PD: Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. Mol Ther (2009) 17(4):742-749.
61. de Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS, van Tinteren H, Mesman EM, Song JY, Schumacher TN: TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 181(4):2563-2571.
62. Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS, Rosenberg SA et al: Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother (2009) 58(3):383-394.
63. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC et al: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 114(3): 535-546.
64. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
65. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 23(10):2346-2357.
66. Burns WR, Zheng Z, Rosenberg SA, Morgan RA: Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood (2009) 114(14):2888-2899.
67. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Pérarnau B: HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J Exp Med (1997) 185(12):2043-2051.
68. Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC et al: Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 116(5):981-989.e1.